SPX3,788.12-30.71 -0.80%
DIA307.76-2.29 -0.74%
IXIC11,050.46-127.44 -1.14%

BRIEF-Mydecine Provides Company Update; Welcomes New Board Member

reuters.com · 06/09/2022 07:38
BRIEF-Mydecine Provides Company Update; Welcomes New Board Member

- Mydecine Innovations Group Inc MYCOF:

  • MYDECINE PROVIDES COMPANY UPDATE; WELCOMES NEW BOARD MEMBER

  • MYDECINE INNOVATIONS GROUP INC - PIVOTED OUR CLINICAL TRIAL STRATEGY FROM A SEAMLESS PHASE 2/3 DESIGN, TO A PHASE 2B AND SUBSEQUENT PHASE 3 STUDY

  • MYDECINE INNOVATIONS GROUP INC - INCREASED NUMBER OF SUBJECTS FOR PHASE 2B TRIAL AND ARE OPTIMISTIC THAT IT WILL BE CONSIDERED A PIVOTAL STUDY BY FDA

  • MYDECINE INNOVATIONS GROUP INC - PLANS TO SUBMIT FULL BREAKTHROUGH THERAPY STATUS AND INVESTIGATIONAL NEW DRUG APPLICATIONS IN EARLY Q4 2022

Source text for Eikon: ID:nGNX75RGWL

Further company coverage: MYCOF


((Reuters.Briefs@thomsonreuters.com;))